SEHK:1177Pharmaceuticals
Sino Biopharmaceutical (SEHK:1177) Half Year Loss Tests Premium 39.7x P/E Narrative
Sino Biopharmaceutical (SEHK:1177) has just posted its FY 2025 results, with second half revenue of C¥14.3b and basic EPS of C¥0.06 loss, while the trailing twelve months show revenue of C¥31.8b and basic EPS of C¥0.13. Over recent reporting periods the company has seen revenue move from C¥13.0b in the second half of FY 2024 to C¥17.6b in the first half of FY 2025, alongside EPS shifting from C¥0.03 to C¥0.19 before the latest half year loss. This creates a mixed picture that puts the focus...